Human Genomics (Aug 2023)

An AI-powered patient triage platform for future viral outbreaks using COVID-19 as a disease model

  • Georgia Charkoftaki,
  • Reza Aalizadeh,
  • Alvaro Santos-Neto,
  • Wan Ying Tan,
  • Emily A. Davidson,
  • Varvara Nikolopoulou,
  • Yewei Wang,
  • Brian Thompson,
  • Tristan Furnary,
  • Ying Chen,
  • Elsio A. Wunder,
  • Andreas Coppi,
  • Wade Schulz,
  • Akiko Iwasaki,
  • Richard W. Pierce,
  • Charles S. Dela Cruz,
  • Gary V. Desir,
  • Naftali Kaminski,
  • Shelli Farhadian,
  • Kirill Veselkov,
  • Rupak Datta,
  • Melissa Campbell,
  • Nikolaos S. Thomaidis,
  • Albert I. Ko,
  • Yale IMPACT Study Team,
  • David C. Thompson,
  • Vasilis Vasiliou

DOI
https://doi.org/10.1186/s40246-023-00521-4
Journal volume & issue
Vol. 17, no. 1
pp. 1 – 17

Abstract

Read online

Abstract Over the last century, outbreaks and pandemics have occurred with disturbing regularity, necessitating advance preparation and large-scale, coordinated response. Here, we developed a machine learning predictive model of disease severity and length of hospitalization for COVID-19, which can be utilized as a platform for future unknown viral outbreaks. We combined untargeted metabolomics on plasma data obtained from COVID-19 patients (n = 111) during hospitalization and healthy controls (n = 342), clinical and comorbidity data (n = 508) to build this patient triage platform, which consists of three parts: (i) the clinical decision tree, which amongst other biomarkers showed that patients with increased eosinophils have worse disease prognosis and can serve as a new potential biomarker with high accuracy (AUC = 0.974), (ii) the estimation of patient hospitalization length with ± 5 days error (R2 = 0.9765) and (iii) the prediction of the disease severity and the need of patient transfer to the intensive care unit. We report a significant decrease in serotonin levels in patients who needed positive airway pressure oxygen and/or were intubated. Furthermore, 5-hydroxy tryptophan, allantoin, and glucuronic acid metabolites were increased in COVID-19 patients and collectively they can serve as biomarkers to predict disease progression. The ability to quickly identify which patients will develop life-threatening illness would allow the efficient allocation of medical resources and implementation of the most effective medical interventions. We would advocate that the same approach could be utilized in future viral outbreaks to help hospitals triage patients more effectively and improve patient outcomes while optimizing healthcare resources.